Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence

Dec 10, 2021Psychiatry research

How often symptoms get worse after ketamine infusions in hard-to-treat depression: Data from a Canadian treatment center

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗

Abstract

The frequency of clinically significant worsening of depressive symptoms during IV ketamine treatment for treatment-resistant depression ranges from 1.83% to 5.49%.

A total of 164 adults with treatment-resistant depression were analyzed.
Symptomatic worsening was defined as a ≥20% increase in scores on the Quick Inventory for Depression Symptomatology-Self Report-16.
No patients with bipolar treatment-resistant depression reported symptomatic worsening.
The rates of worsening observed are comparable to those associated with conventional antidepressants.
The results are based on a retrospective analysis and have limitations due to the study's single-centered and uncontrolled design.

AI simplified

Antidepressants are associated with symptomatic worsening in a subgroup of patients. Replicated evidence has demonstrated rapid and robust antidepressant effects with intravenous (IV) ketamine in treatment resistant depression (TRD); however, the risk of ketamine worsening depressive symptoms in a subgroup of patients remains unknown. Herein we report a retrospective analysis on the rates of symptomatic worsening during an acute course of IV ketamine in individuals with unipolar (n = 142) and bipolar (n = 22) TRD. Adults (N = 164; mean age = 45.97) with TRD underwent four sub-anesthetic infusions (0.5-0.75 mg/kg over 40 min) of IV ketamine over two weeks, and were assessed with the Quick Inventory for Depression Symptomatology-Self Report-16 (QIDS-SR) at baseline and after each infusion. The primary outcome was the proportion of patients experiencing clinically significant worsening of depressive symptoms (≥20% increase on the QIDS-SR) at each time point relative to baseline. Secondary analyses explored trends in the results. The frequency of clinically significant worsening fluctuated between 1.83% to 5.49%, with no identifiable trend across time. Zero individuals with bipolar TRD reported symptomatic worsening. Limitations include the single-centered, uncontrolled, retrospective nature of this study. Rates of symptomatic worsening associated with IV ketamine therapy for TRD appear to be very low and similar to conventional antidepressants. 16 16

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief